Literature DB >> 16511589

Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis.

Philippe Lefebvre1, Giulia Chinetti, Jean-Charles Fruchart, Bart Staels.   

Abstract

PPARalpha is a nuclear receptor that regulates liver and skeletal muscle lipid metabolism as well as glucose homeostasis. Acting as a molecular sensor of endogenous fatty acids (FAs) and their derivatives, this ligand-activated transcription factor regulates the expression of genes encoding enzymes and transport proteins controlling lipid homeostasis, thereby stimulating FA oxidation and improving lipoprotein metabolism. PPARalpha also exerts pleiotropic antiinflammatory and antiproliferative effects and prevents the proatherogenic effects of cholesterol accumulation in macrophages by stimulating cholesterol efflux. Cellular and animal models of PPARalpha help explain the clinical actions of fibrates, synthetic PPARalpha agonists used to treat dyslipidemia and reduce cardiovascular disease and its complications in patients with the metabolic syndrome. Although these preclinical studies cannot predict all of the effects of PPARalpha in humans, recent findings have revealed potential adverse effects of PPARalpha action, underlining the need for further study. This Review will focus on the mechanisms of action of PPARalpha in metabolic diseases and their associated vascular pathologies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16511589      PMCID: PMC1386122          DOI: 10.1172/JCI27989

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  123 in total

1.  Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus.

Authors:  David A Playford; Gerald F Watts; James D Best; Valerie Burke
Journal:  Am J Cardiol       Date:  2002-12-01       Impact factor: 2.778

2.  DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha.

Authors:  Philippe Delerive; Karolien De Bosscher; Wim Vanden Berghe; Jean-Charles Fruchart; Guy Haegeman; Bart Staels
Journal:  Mol Endocrinol       Date:  2002-05

3.  WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha ) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice.

Authors:  Chieh J Chou; Martin Haluzik; Charmaine Gregory; Kelly R Dietz; Charles Vinson; Oksana Gavrilova; Marc L Reitman
Journal:  J Biol Chem       Date:  2002-05-06       Impact factor: 5.157

4.  Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT).

Authors:  Sander J Robins; Hanna Bloomfield Rubins; Fred H Faas; Ernst J Schaefer; Marshall B Elam; James W Anderson; Dorothea Collins
Journal:  Diabetes Care       Date:  2003-05       Impact factor: 19.112

5.  Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.

Authors:  Gerald F Watts; P Hugh R Barrett; Juying Ji; Adrian P Serone; Dick C Chan; Kevin D Croft; Franziska Loehrer; Anthony G Johnson
Journal:  Diabetes       Date:  2003-03       Impact factor: 9.461

6.  Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism.

Authors:  Andries J Gilde; Karin A J M van der Lee; Peter H M Willemsen; Giulia Chinetti; Feike R van der Leij; Ger J van der Vusse; Bart Staels; Marc van Bilsen
Journal:  Circ Res       Date:  2003-02-06       Impact factor: 17.367

7.  Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta.

Authors:  Deborah M Muoio; Paul S MacLean; David B Lang; Shi Li; Joseph A Houmard; James M Way; Deborah A Winegar; J Christopher Corton; G Lynis Dohm; William E Kraus
Journal:  J Biol Chem       Date:  2002-05-06       Impact factor: 5.157

8.  Peroxisome proliferator-activated receptor alpha (PPARalpha ) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes.

Authors:  Christophe Blanquart; Olivier Barbier; Jean-Charles Fruchart; Bart Staels; Corine Glineur
Journal:  J Biol Chem       Date:  2002-07-12       Impact factor: 5.157

9.  Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size.

Authors:  Nicole S Wayman; Yoshiyuki Hattori; Michelle C McDonald; Helder Mota-Filipe; Salvatore Cuzzocrea; Babrbara Pisano; Prabal K Chatterjee; Christoph Thiemermann
Journal:  FASEB J       Date:  2002-07       Impact factor: 5.191

10.  Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators.

Authors:  Ngoc Vu-Dac; Philippe Gervois; Heidi Jakel; Maxime Nowak; Eric Bauge; Helene Dehondt; Bart Staels; Len A Pennacchio; Edward M Rubin; Jamila Fruchart-Najib; Jean-Charles Fruchart
Journal:  J Biol Chem       Date:  2003-03-12       Impact factor: 5.157

View more
  292 in total

1.  Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21.

Authors:  Holly A Cyphert; Xuemei Ge; Alison B Kohan; Lisa M Salati; Yanqiao Zhang; F Bradley Hillgartner
Journal:  J Biol Chem       Date:  2012-06-01       Impact factor: 5.157

Review 2.  Nuclear hormone receptors in diabetic nephropathy.

Authors:  Xiaoxin X Wang; Tao Jiang; Moshe Levi
Journal:  Nat Rev Nephrol       Date:  2010-04-27       Impact factor: 28.314

3.  Comparative studies of skeletal muscle proteome and transcriptome profilings between pig breeds.

Authors:  Nam-Kuk Kim; Hye-Ran Park; Hwi-Cheul Lee; Duhak Yoon; Eun-Suk Son; Yeun-Song Kim; Se-Ra Kim; Oun-Hyun Kim; Chang-Soo Lee
Journal:  Mamm Genome       Date:  2010-06-08       Impact factor: 2.957

4.  NR4A Orphan Nuclear Receptors in Cardiovascular Biology.

Authors:  Yue Zhao; Dennis Bruemmer
Journal:  Drug Discov Today Dis Mech       Date:  2009

5.  Proteome Dynamics Reveals Pro-Inflammatory Remodeling of Plasma Proteome in a Mouse Model of NAFLD.

Authors:  Ling Li; Gurkan Bebek; Stephen F Previs; Jonathan D Smith; Rovshan G Sadygov; Arthur J McCullough; Belinda Willard; Takhar Kasumov
Journal:  J Proteome Res       Date:  2016-08-05       Impact factor: 4.466

6.  E2/ERβ Inhibits PPARα to Regulate Cell-Proliferation and Enhance Apoptosis in Hep3B-Hepatocellular Carcinoma.

Authors:  Shu Nu Chang-Lee; Hsi-Hsien Hsu; Marthandam Asokan Shibu; Tsung-Jung Ho; Chih-Hao Tsai; Ming-Cheng Chen; Chuan-Chou Tu; Vijaya Padma Viswanadha; Wei- Wen Kuo; Chih-Yang Huang
Journal:  Pathol Oncol Res       Date:  2016-10-18       Impact factor: 3.201

7.  MicroRNA-33a promotes cell proliferation and inhibits apoptosis by targeting PPARα in human hepatocellular carcinoma.

Authors:  Weiping Chang; Lei Zhang; Yao Xian; Zhaoxiang Yu
Journal:  Exp Ther Med       Date:  2017-03-20       Impact factor: 2.447

8.  SIRT4 represses peroxisome proliferator-activated receptor α activity to suppress hepatic fat oxidation.

Authors:  Gaëlle Laurent; Vincent C J de Boer; Lydia W S Finley; Meredith Sweeney; Hong Lu; Thaddeus T Schug; Yana Cen; Seung Min Jeong; Xiaoling Li; Anthony A Sauve; Marcia C Haigis
Journal:  Mol Cell Biol       Date:  2013-09-16       Impact factor: 4.272

Review 9.  New approaches to target microsomal triglyceride transfer protein.

Authors:  Mohammed Mahmood Hussain; Ahmed Bakillah
Journal:  Curr Opin Lipidol       Date:  2008-12       Impact factor: 4.776

Review 10.  Minireview: Won't get fooled again: the nonmetabolic roles of peroxisome proliferator-activated receptors (PPARs) in the heart.

Authors:  Pamela Lockyer; Jonathan C Schisler; Cam Patterson; Monte S Willis
Journal:  Mol Endocrinol       Date:  2009-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.